BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30859432)

  • 1. TSH suppression aggravates arterial inflammation - an
    Boswijk E; Sanders KJC; Broeders EPM; de Ligt M; Vijgen GHEJ; Havekes B; Mingels AMA; Wierts R; van Marken Lichtenbelt WD; Schrauwen P; Mottaghy FM; Wildberger JE; Bucerius J
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1428-1438. PubMed ID: 30859432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of
    Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
    Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma.
    Petrich T; Börner AR; Otto D; Hofmann M; Knapp WH
    Eur J Nucl Med Mol Imaging; 2002 May; 29(5):641-7. PubMed ID: 11976802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation.
    van Tol KM; Jager PL; Piers DA; Pruim J; de Vries EG; Dullaart RP; Links TP
    Thyroid; 2002 May; 12(5):381-7. PubMed ID: 12097198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal threshold of stimulated serum thyroglobulin level for
    Chai H; Zhang H; Yu YL; Gao YC
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):429-432. PubMed ID: 28585147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary 18F-FDG uptake correlates with serum TSH levels in thyroid cancer patients on 18F-FDG PET/CT.
    Ding Y; Wu S; Xu J; Wang H; Ma C
    Nucl Med Commun; 2019 Jan; 40(1):57-62. PubMed ID: 30422898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Follow-up of differentiated thyroid cancer patients using rhTSH--preliminary results].
    Petrich T; Börner AR; Weckesser E; Soudah B; Otto D; Widjaja A; Hofmann M; Kreipe HH; Knapp WH
    Nuklearmedizin; 2001 Feb; 40(1):7-14. PubMed ID: 11373937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subclinical systemic and vascular inflammation detected by (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with mild psoriasis.
    Youn SW; Kang SY; Kim SA; Park GY; Lee WW
    J Dermatol; 2015 Jun; 42(6):559-66. PubMed ID: 25807844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.
    Moog F; Linke R; Manthey N; Tiling R; Knesewitsch P; Tatsch K; Hahn K
    J Nucl Med; 2000 Dec; 41(12):1989-95. PubMed ID: 11138683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
    Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-related aortic inflammatory response, as assessed with
    Vlachopoulos C; Terentes-Printzios D; Katsaounou P; Solomou E; Gardikioti V; Exarchos D; Economou D; Christopoulou G; Kalkinis AD; Kafouris P; Antonopoulos A; Lazaros G; Kotanidou A; Datseris I; Tsioufis K; Anagnostopoulos C
    J Nucl Cardiol; 2023 Feb; 30(1):74-82. PubMed ID: 35501458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level.
    Bertagna F; Bosio G; Biasiotto G; Rodella C; Puta E; Gabanelli S; Lucchini S; Merli G; Savelli G; Giubbini R; Rosenbaum J; Alavi A
    Clin Nucl Med; 2009 Nov; 34(11):756-61. PubMed ID: 19851169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Canadian Study of Arterial Inflammation in Patients with Diabetes and Recent Vascular Events, Evaluation of Colchicine Effectiveness (CADENCE): protocol for a randomised, double-blind, placebo-controlled trial.
    Boczar KE; Shin S; deKemp RA; Dowlatshahi D; Tavoosi A; Wiefels C; Liu P; Lochnan H; MacPherson PA; Chong AY; Torres C; Leung E; Tawakol A; Ahmadi A; Garrard L; Lefebvre C; Kelly C; MacPhee P; Tilokee E; Raggi P; Wells GA; Beanlands R
    BMJ Open; 2023 Nov; 13(11):e074463. PubMed ID: 37949621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aortic stiffness and left ventricular function in patients with differentiated thyroid cancer.
    Gazdag A; Nagy EV; Erdei A; Bodor M; Berta E; Szabó Z; Jenei Z
    J Endocrinol Invest; 2015 Feb; 38(2):133-42. PubMed ID: 25194423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thresholds for Arterial Wall Inflammation Quantified by
    van der Valk FM; Verweij SL; Zwinderman KA; Strang AC; Kaiser Y; Marquering HA; Nederveen AJ; Stroes ES; Verberne HJ; Rudd JH
    JACC Cardiovasc Imaging; 2016 Oct; 9(10):1198-1207. PubMed ID: 27639759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T; Kowalska A; Lesiak J; Młynarczyk J
    Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
    Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
    Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma.
    Triviño Ibáñez EM; Muros MA; Torres Vela E; Llamas Elvira JM
    Endocrine; 2016 Mar; 51(3):490-8. PubMed ID: 26224589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.